Eton Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
Eton Pharmaceuticals, Inc. (ETON) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $389.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2026-03-19
- Eton Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2025 was $389.00K, a 130.18% increase from fiscal 2024.
- Eton Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $169.00K.
- Eton Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was $0.00.
- Eton Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2022 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2025-12-31 | $389.00K 10-K · filed 2026-03-19 |
| 2024-12-31 | $169.00K 10-K · filed 2026-03-19 |
| 2023-12-31 | $0.00 10-K · filed 2026-03-19 |
| 2022-12-31 | $0.00 10-K · filed 2025-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |